Coagulation abnormalities in patients with Gaucher's disease

Effect of therapy

Henny H. Billett, S. Rizvi, A. Sawitsky

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Various coagulation defects have been associated with Gaucher's disease, including factor IX deficiency and acquired von Willebrand's disease (VWD). We performed repeated coagulation assays in 9 patients with Gaucher's disease over a period of 2 years. The prothrombin time (PT) and fibrinogen levels were normal in 8 of 9 patients, while the partial thromboplastin time (PTT) was abnormal in 5 of 9; all mixing PTT tests showed correction. Factor IX was normal repeatedly in the 7 of 7 patients tested. In contrast, factor XI was decreased in 3 of 9 patients assayed. Anticardiolipin (ACL) IgM was normal in all patients. ACL IgG was highly variable; levels were abnormal at least once in 6 of 8 patients, but were also normal at least once in 7 of 8 patients. Factor VIII was also quite variable: levels were decreased at least once in 4 of 9 patients, and normal at least once in 8 of 9 patients. Von Willebrand factor antigen (VWF Ag) studies were normal in 7 of 8 patients, but VWF activity was decreased at least once in 4 of 8 patients. In some patients, these problems could be overcome by specimen dilution. In only 1 patient was VWF Ag decreased; this patient had a factor VIIIC level of 13%, and VWF activity of 18.7%. Coagulation assays performed before and after alglucerase administration failed to demonstrate any significant improvement in these assays, and neither was there a consistent improvement over the duration of therapy. We suggest that previously reported decreases in factor IX and VWF may be secondary to the interfering presence of increased cerebroside levels. Caution must be used in the interpretation of clotting assays in the patient with Gaucher's disease.

Original languageEnglish (US)
Pages (from-to)234-236
Number of pages3
JournalAmerican Journal of Hematology
Volume51
Issue number3
DOIs
StatePublished - Mar 1996

Fingerprint

Gaucher Disease
Therapeutics
Factor IX
Partial Thromboplastin Time
Factor VIII
von Willebrand Factor
Factor XI
Cerebrosides
Hemophilia B
von Willebrand Diseases
Prothrombin Time

Keywords

  • Alglucerase therapy
  • Coagulopathies
  • Gaucher's disease

ASJC Scopus subject areas

  • Hematology

Cite this

Coagulation abnormalities in patients with Gaucher's disease : Effect of therapy. / Billett, Henny H.; Rizvi, S.; Sawitsky, A.

In: American Journal of Hematology, Vol. 51, No. 3, 03.1996, p. 234-236.

Research output: Contribution to journalArticle

@article{8241e1f4aeee49abaf05bf9a00caa788,
title = "Coagulation abnormalities in patients with Gaucher's disease: Effect of therapy",
abstract = "Various coagulation defects have been associated with Gaucher's disease, including factor IX deficiency and acquired von Willebrand's disease (VWD). We performed repeated coagulation assays in 9 patients with Gaucher's disease over a period of 2 years. The prothrombin time (PT) and fibrinogen levels were normal in 8 of 9 patients, while the partial thromboplastin time (PTT) was abnormal in 5 of 9; all mixing PTT tests showed correction. Factor IX was normal repeatedly in the 7 of 7 patients tested. In contrast, factor XI was decreased in 3 of 9 patients assayed. Anticardiolipin (ACL) IgM was normal in all patients. ACL IgG was highly variable; levels were abnormal at least once in 6 of 8 patients, but were also normal at least once in 7 of 8 patients. Factor VIII was also quite variable: levels were decreased at least once in 4 of 9 patients, and normal at least once in 8 of 9 patients. Von Willebrand factor antigen (VWF Ag) studies were normal in 7 of 8 patients, but VWF activity was decreased at least once in 4 of 8 patients. In some patients, these problems could be overcome by specimen dilution. In only 1 patient was VWF Ag decreased; this patient had a factor VIIIC level of 13{\%}, and VWF activity of 18.7{\%}. Coagulation assays performed before and after alglucerase administration failed to demonstrate any significant improvement in these assays, and neither was there a consistent improvement over the duration of therapy. We suggest that previously reported decreases in factor IX and VWF may be secondary to the interfering presence of increased cerebroside levels. Caution must be used in the interpretation of clotting assays in the patient with Gaucher's disease.",
keywords = "Alglucerase therapy, Coagulopathies, Gaucher's disease",
author = "Billett, {Henny H.} and S. Rizvi and A. Sawitsky",
year = "1996",
month = "3",
doi = "10.1002/(SICI)1096-8652(199603)51:3<234::AID-AJH9>3.0.CO;2-Y",
language = "English (US)",
volume = "51",
pages = "234--236",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Coagulation abnormalities in patients with Gaucher's disease

T2 - Effect of therapy

AU - Billett, Henny H.

AU - Rizvi, S.

AU - Sawitsky, A.

PY - 1996/3

Y1 - 1996/3

N2 - Various coagulation defects have been associated with Gaucher's disease, including factor IX deficiency and acquired von Willebrand's disease (VWD). We performed repeated coagulation assays in 9 patients with Gaucher's disease over a period of 2 years. The prothrombin time (PT) and fibrinogen levels were normal in 8 of 9 patients, while the partial thromboplastin time (PTT) was abnormal in 5 of 9; all mixing PTT tests showed correction. Factor IX was normal repeatedly in the 7 of 7 patients tested. In contrast, factor XI was decreased in 3 of 9 patients assayed. Anticardiolipin (ACL) IgM was normal in all patients. ACL IgG was highly variable; levels were abnormal at least once in 6 of 8 patients, but were also normal at least once in 7 of 8 patients. Factor VIII was also quite variable: levels were decreased at least once in 4 of 9 patients, and normal at least once in 8 of 9 patients. Von Willebrand factor antigen (VWF Ag) studies were normal in 7 of 8 patients, but VWF activity was decreased at least once in 4 of 8 patients. In some patients, these problems could be overcome by specimen dilution. In only 1 patient was VWF Ag decreased; this patient had a factor VIIIC level of 13%, and VWF activity of 18.7%. Coagulation assays performed before and after alglucerase administration failed to demonstrate any significant improvement in these assays, and neither was there a consistent improvement over the duration of therapy. We suggest that previously reported decreases in factor IX and VWF may be secondary to the interfering presence of increased cerebroside levels. Caution must be used in the interpretation of clotting assays in the patient with Gaucher's disease.

AB - Various coagulation defects have been associated with Gaucher's disease, including factor IX deficiency and acquired von Willebrand's disease (VWD). We performed repeated coagulation assays in 9 patients with Gaucher's disease over a period of 2 years. The prothrombin time (PT) and fibrinogen levels were normal in 8 of 9 patients, while the partial thromboplastin time (PTT) was abnormal in 5 of 9; all mixing PTT tests showed correction. Factor IX was normal repeatedly in the 7 of 7 patients tested. In contrast, factor XI was decreased in 3 of 9 patients assayed. Anticardiolipin (ACL) IgM was normal in all patients. ACL IgG was highly variable; levels were abnormal at least once in 6 of 8 patients, but were also normal at least once in 7 of 8 patients. Factor VIII was also quite variable: levels were decreased at least once in 4 of 9 patients, and normal at least once in 8 of 9 patients. Von Willebrand factor antigen (VWF Ag) studies were normal in 7 of 8 patients, but VWF activity was decreased at least once in 4 of 8 patients. In some patients, these problems could be overcome by specimen dilution. In only 1 patient was VWF Ag decreased; this patient had a factor VIIIC level of 13%, and VWF activity of 18.7%. Coagulation assays performed before and after alglucerase administration failed to demonstrate any significant improvement in these assays, and neither was there a consistent improvement over the duration of therapy. We suggest that previously reported decreases in factor IX and VWF may be secondary to the interfering presence of increased cerebroside levels. Caution must be used in the interpretation of clotting assays in the patient with Gaucher's disease.

KW - Alglucerase therapy

KW - Coagulopathies

KW - Gaucher's disease

UR - http://www.scopus.com/inward/record.url?scp=0029866861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029866861&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8652(199603)51:3<234::AID-AJH9>3.0.CO;2-Y

DO - 10.1002/(SICI)1096-8652(199603)51:3<234::AID-AJH9>3.0.CO;2-Y

M3 - Article

VL - 51

SP - 234

EP - 236

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -